Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFAPYRIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFAPYRIDINE.
SODIUM SULFACETAMIDE vs SULFAPYRIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
None Documented
None Documented
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic